






































Strategic Alliances, Joint Ventures and Licensing

2016: Market leaders in life sciences, technology, energy, cleantech, communications, financial services and many other industries turn to WilmerHale for legal advice and business insights. Our corporate, licensing, intellectual property and regulatory lawyers regularly handle a broad range of strategic alliance, joint venture, licensing, collaboration, product development, outsourcing, manufacturing, distribution and similar agreements, including many significant deals that are helping to shape the future of science, technology and commerce. We have advised clients throughout the United States, Europe and Asia on strategic alliances that have received industry recognition for their importance, and our lawyers are recognized as global leaders in these fields. The following is a selection of our recent transactions.

Counsel of Choice for Strategic Alliances, Joint Ventures and Licensing

SERVING INDUSTRY LEADERS IN LIFE SCIENCES, TECHNOLOGY, ENERGY AND CLEANTECH, COMMUNICATIONS, FINANCIAL SERVICES AND BEYOND



 <i>Reacquisition of tazemetostat rights from Eisai and restructuring of collaboration with Celgene</i>	 <i>Outsourcing agreement</i>	 <i>Microbiome pharmaceutical licensing advice</i>	 <i>Sponsorship and athlete contracts</i>	 <i>Licensing and transactional advice</i>	 <i>Licensing and settlement agreements</i>	 <i>Collaboration with Astellas to develop immuno-oncology therapeutics</i>	 <i>Technology development agreements</i>	 <i>Antibody discovery platform license with Merck</i>
 <i>Patent licensing, acquisition and sale transactions</i>	 <i>Cloud services agreement with First Data</i>	 <i>Research and development arrangements</i>	 <i>Video game distribution agreements</i>	 <i>Outsourcing agreements</i>	 <i>Drug development and commercialization agreements</i>	 <i>Collaboration agreements and IP advice</i>	 <i>Movie and TV studio agreements</i>	 <i>Collaboration and licensing agreement advice</i>
 <i>Hepatitis C collaboration with Janssen Pharmaceuticals</i>	 <i>Domestic and international outsourcing transactions</i>	 <i>Development and commercialization agreements</i>	 <i>Expansion of antibody-drug conjugate collaboration with Mersana Therapeutics</i>	 <i>Collaboration with Agenus to develop immuno-oncology antibodies</i>	 <i>Collaboration and licensing agreement advice</i>	 <i>Collaboration with Astellas, Affinivax and the University of Maryland to develop nosocomial infection vaccines</i>	 <i>Cancer immunotherapy collaboration with Juno Therapeutics</i>	 <i>Licensing agreement with TMRC Co. Ltd. for tamibarotene</i>
 <i>Collaboration with Parion Sciences to develop epithelial sodium channel inhibitors for pulmonary diseases</i>	 <i>Collaboration with Roche for the development of a TLR inhibitor</i>	 <i>Banking SaaS agreements</i>	 <i>Collaboration with Sanofi for the development and commercialization of sotagliflozin</i>	 <i>Grant agreement with Cystic Fibrosis Foundation Therapeutics</i>	 <i>Licensing advice</i>	 <i>Licensing and transactional advice, including strategic relationship with vRad</i>	 <i>Licensing of MIFARE technology from NXP</i>	 <i>Licensing and transactional advice</i>



Mixed Sources
 Product group from well-managed
 forests, controlled sources and
 recycled wood or fiber
www.fsc.org Cert no. BV-COC-070904
 © 1996 Forest Stewardship Council

16_0218 KW 4/16 3000

WilmerHale recognizes its corporate responsibility to environmental stewardship.

Connect with us   

wilmerhale.com

Wilmer Cutler Pickering Hale and Dorr LLP is a Delaware limited liability partnership. WilmerHale principal law offices: 60 State Street, Boston, Massachusetts 02109, +1 617 526 6000; 1875 Pennsylvania Avenue, NW, Washington, DC 20006, +1 202 663 6000. Our United Kingdom office is operated under a separate Delaware limited liability partnership of solicitors and registered foreign lawyers authorized and regulated by the Solicitors Regulation Authority (SRA No. 287488). Our professional rules can be found at www.sra.org.uk/solicitors/code-of-conduct.page. A list of partners and their professional qualifications is available for inspection at our UK office. In Beijing, we are registered to operate as a Foreign Law Firm Representative Office. This material is for general informational purposes only and does not represent our advice as to any particular set of facts; nor does it represent any undertaking to keep recipients advised of all legal developments. Prior results do not guarantee a similar outcome. © 2016 Wilmer Cutler Pickering Hale and Dorr LLP